Data for the Certolizumab NMA-network discussed in Dias et al. (2013)

Data are available from a review of trials of certolizumab pegol (CZP) for the treatment of rheumatoid arthritis in patients who had failed on disease-modifying antirheumatic drugs, including methotrexate (MTX). 20 Twelve MTX controlled trials were identified, comparing 6 different treatments with placebo. The primary outcome is improving by at least 50 of Rheumatology scale (ACR50) at 6 months. A trial-specificc covariate, the mean disease duration in years for patients, is also given.

Certolizumabdat

Format

An object of class data.frame with 12 rows and 9 columns.

Source

Dias, S., Sutton, A.J., Welton, N.J. and Ades, A.E., 2013. Evidence synthesis for decision making 3 heterogeneity-subgroups, meta-regression, bias, and bias-adjustment. Medical Decision Making, 33(5), pp.618-640.